Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2023.10.005 | DOI Listing |
Publication Analysis
Top Keywords
patients tp53
8
tp53 wild-type
8
selinexor changing
4
changing paradigm
4
paradigm patients
4
wild-type endometrial
4
endometrial cancer?
4
cancer? recurrent
4
recurrent endometrial
4
endometrial cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!